"Glucagon-Like Peptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.
| Descriptor ID |
D004763
|
| MeSH Number(s) |
D06.472.317.469.500
|
| Concept/Terms |
Glucagon-Like Peptides- Glucagon-Like Peptides
- Glucagon Like Peptides
- Glucagon-Like Polypeptides
- Glucagon Like Polypeptides
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptides".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptides".
This graph shows the total number of publications written about "Glucagon-Like Peptides" by people in this website by year, and whether "Glucagon-Like Peptides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 |
| 1996 | 1 | 1 | 2 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 4 | 5 |
| 2005 | 1 | 3 | 4 |
| 2006 | 2 | 2 | 4 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 3 | 4 |
| 2014 | 5 | 0 | 5 |
| 2015 | 2 | 3 | 5 |
| 2016 | 5 | 0 | 5 |
| 2017 | 15 | 2 | 17 |
| 2018 | 17 | 10 | 27 |
| 2019 | 15 | 9 | 24 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucagon-Like Peptides" by people in Profiles.
-
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. Diabetes Care. 2019 11; 42(11):2108-2116.
-
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care. 2019 12; 42(12):2262-2271.
-
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019 11; 7(11):834-844.
-
[Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)]. Rev Med Liege. 2019 Sep; 74(9):488-494.
-
Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial. Diabetes Obes Metab. 2019 11; 21(11):2570-2575.
-
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019 09; 42(9):1724-1732.
-
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019 08 29; 381(9):841-851.
-
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019 07 13; 394(10193):131-138.
-
Is it time to REWIND the cardiorenal clock in diabetes? Lancet. 2019 07 13; 394(10193):95-97.
-
Pioneering oral peptide therapy for patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2019 07; 7(7):500-502.